Bretylium’s adrenaline-blocking effect may lead to various other benefits aswell. In 31 % of individuals acquiring bretylium, the evolving heart attack did not turn into a ‘true’ myocardial infarction, with long term damage to the heart muscles. On the other hand, 95 % of patients treated with lidocaine designed a large heart attack. Related StoriesNew check for coronary attack may conserve NHS millionsSupport for enteric nervous system pathology in prodromal PDLowering blood pressure below presently recommended targets reduces risk of stroke, center attackA clue to the importance of blocking the sympathetic nervous system was that bretylium-treated sufferers remained warm and dry, with normal pores and skin. In contrast, sufferers receiving lidocaine were pale, sweaty, and cool, all signals of sympathetic nervous program activation.Full information on the findings are released online today before publication in the British Medical Journal and Wellness Technology Assessment.. Can-Fite BioPharma completes RA Phase III research of lead drug candidate CF101 Can-Fite BioPharma Ltd. , a biotechnology company with a pipeline of proprietary small molecule drugs that address tumor and inflammatory diseases, announced today that it finished the design of the Rheumatoid Arthritis Phase III research of its lead medication applicant CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study.